MAPT and Alzheimer disease: However, a more recent study showed that GSK-3β is crucially implicated in AD and PD through the direct interaction with tau, β-amyloid, and α-synuclein [57], which suggested that GSK-3β inhibition has become an attractive target for therapeutic intervention against AD and PD.